-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
Author: info
On March 28, the CDE official website showed that the domestic clinical application of Hebo Medicine’s B7H4x4-1BB double antibody was accepted for the treatment of solid tumors
HBM7008 was developed by Harbin Pharmaceutical's unique and innovative HBICE platform.
HBM7008 specifically activates T cells and produces antitumor activity only when it binds to B7H4
The unique tumor expression specificity and immunomodulatory activity of HBM7008 is expected to produce better efficacy in PD-L1-negative patients or patients who are resistant to PD-1/PD-L1 immunotherapy drugs
On February 28 this year, HBM7008 was approved for clinical use in Australia